Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma.

摘要: Purpose: To determine the clinical relevance of p27 Kip1 in multiple myeloma (MM), we examined relationship between expression at diagnosis and as well laboratory parameters, including response to chemotherapy overall survival 74 previously untreated patients with MM. Experimental Design: Expression was assessed by immunohistochemistry on formalin-fixed, paraffin-embedded bone marrow biopsies. classified low (≤5% -positive cells) or high (>5% cells). Results: Low observed 23 (31%) patients. The rate standard dose (including vincristine, doxorubicin, dexamethasone induction before high-dose chemotherapy) 70%, no significant difference (83 versus 65%; P = 0.1). Kaplan-Meier analysis all revealed that had a significantly shorter (median, 3.7 years 4.7 years; 0.03) than those expression. Patients receiving experienced prolonged compared (median not yet reached 2.9 0.008). By multivariate Cox regression analyses, ( 0.03), deletion chromosome 13q14 0.02), β 2 -microglobulin 0.01) were identified independent adverse prognostic factors for survival. According number unfavorable present each patient, low-risk, intermediate-risk, high-risk different times defined survival, 6.3 4.2 1.8 0.001). Conclusions: is an factor proposed risk score might be useful risk-adapted treatment future.